Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-MUC1 monoclonal antibody - OncoQuest

Next Previous
X
Search
Drug Profile

Anti-MUC1 monoclonal antibody - OncoQuest

Alternative Names: Anti-MUC1 AR20.5; Anti-MUC1 mAb - Quest PharmaTech; AR20.5; BrevaRex; mAb-AR20.5

Latest Information Update: 27 Apr 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AltaRex
  • Developer OncoQuest; ViRexx Medical Corp
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Mucin 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Pancreatic cancer
  • Discontinued Breast cancer; Multiple myeloma

Most Recent Events

  • 23 Apr 2024 Endo International has been acquired and merged into Endo, Inc.
  • 21 Aug 2023 Anti-MUC1 monoclonal antibody - OncoQuest receives Orphan Drug status for Pancreatic cancer in USA
  • 11 Feb 2019 OncoQuest completes a phase I trial in Pancreatic cancer (Combination therapy, Neoadjuvant therapy) before February 2019 (Quest PharmaTech Pipeline, February 2019)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top